141 related articles for article (PubMed ID: 24225331)
21. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
22. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
23. Multiple myeloma of the central nervous system: a clinicopathological review.
Al-Sobhi E; Osoba AO; Karar A; Zuraiki AM
East Mediterr Health J; 2009; 15(6):1570-9. PubMed ID: 20218151
[TBL] [Abstract][Full Text] [Related]
24. [Monoclonal gammopathy--multiple myeloma].
Dietzfelbinger H
MMW Fortschr Med; 2005 Jun; 147(24):32-3, 35-6. PubMed ID: 16001531
[TBL] [Abstract][Full Text] [Related]
25. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
[TBL] [Abstract][Full Text] [Related]
26. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
27. Multiple myeloma: new aspects of biology and treatment.
Ozaki S; Kosaka M
J Med Invest; 1998 Feb; 44(3-4):127-36. PubMed ID: 9597800
[TBL] [Abstract][Full Text] [Related]
28. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.
Hagen P; Zhang J; Barton K
Blood Cancer J; 2022 May; 12(5):83. PubMed ID: 35637223
[TBL] [Abstract][Full Text] [Related]
29. Individualized therapy in multiple myeloma: are we there?
Girnius S; Munshi NC
Semin Oncol; 2013 Oct; 40(5):567-76. PubMed ID: 24135401
[TBL] [Abstract][Full Text] [Related]
30. Multiple myeloma: current perspectives.
Slovak ML
Clin Lab Med; 2011 Dec; 31(4):699-724, x. PubMed ID: 22118745
[TBL] [Abstract][Full Text] [Related]
31. High-risk multiple myeloma: does it still exist?
Tuchman SA; Lonial S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S70-6. PubMed ID: 22035753
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of high-risk multiple myeloma patients treated with high-dose chemotherapy].
Kurahashi S; Suzuki K; Sawamoto A; Adachi T; Iwasaki T; Suzuki H; Sugimoto T; Narimatsu H; Hayakawa F; Sugiura I
Rinsho Ketsueki; 2010 Mar; 51(3):174-80. PubMed ID: 20379111
[TBL] [Abstract][Full Text] [Related]
33. Cytogenetics of extramedullary manifestations in multiple myeloma.
Billecke L; Murga Penas EM; May AM; Engelhardt M; Nagler A; Leiba M; Schiby G; Kröger N; Zustin J; Marx A; Matschke J; Tiemann M; Goekkurt E; Heidtmann HH; Vettorazzi E; Dierlamm J; Bokemeyer C; Schilling G
Br J Haematol; 2013 Apr; 161(1):87-94. PubMed ID: 23368088
[TBL] [Abstract][Full Text] [Related]
34. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.
Stewart AK; Bergsagel PL; Greipp PR; Dispenzieri A; Gertz MA; Hayman SR; Kumar S; Lacy MQ; Lust JA; Russell SJ; Witzig TE; Zeldenrust SR; Dingli D; Reeder CB; Roy V; Kyle RA; Rajkumar SV; Fonseca R
Leukemia; 2007 Mar; 21(3):529-34. PubMed ID: 17230230
[TBL] [Abstract][Full Text] [Related]
35. [Clinical Characteristics of Multiple Myeloma Patients with Early Relapse].
Chen T; Ji JM; Li YT; Fan L; Chen LJ; Li JY; Qu XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1144-1149. PubMed ID: 35981375
[TBL] [Abstract][Full Text] [Related]
36. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in the management of multiple myeloma.
Kumar L; Verma R; Radhakrishnan VR
Natl Med J India; 2010; 23(4):210-8. PubMed ID: 21192514
[TBL] [Abstract][Full Text] [Related]
38. The impact of genomics on the management of myeloma.
Corre J; Avet-Loiseau H
J Natl Compr Canc Netw; 2011 Oct; 9(10):1200-6. PubMed ID: 21975916
[TBL] [Abstract][Full Text] [Related]
39. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma.
Chiecchio L; Protheroe RK; Ibrahim AH; Cheung KL; Rudduck C; Dagrada GP; Cabanas ED; Parker T; Nightingale M; Wechalekar A; Orchard KH; Harrison CJ; Cross NC; Morgan GJ; Ross FM
Leukemia; 2006 Sep; 20(9):1610-7. PubMed ID: 16826223
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in multiple myeloma: practicability for clinical practice and future perspectives.
Haferlach T; Löffler H
Leukemia; 1997 Dec; 11 Suppl 5():S5-9. PubMed ID: 9436931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
